Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines. Please watch the video at Investors.com ...

Summit Therapeutics (NASDAQ:SMMT), a drug developer challenging pharma giant Merck's (NYSE:MRK) dominance in lung cancer, won a new buy recommendation from Truist on Wednesday based on its deal ...

announced the Winners of Merck Foundation Africa Research Summit (MARS) Awards 2024, in partnership with International Federation of Fertility Societies -IFFS, Africa Reproductive Care Society ...